Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 597293, 6 pages
http://dx.doi.org/10.1155/2015/597293
Clinical Study

Recombinant Human Thrombopoietin Treatment Promotes Hematopoiesis Recovery in Patients with Severe Aplastic Anemia Receiving Immunosuppressive Therapy

Department of Hematology, General Hospital, Tianjin Medical University, Tianjin 300052, China

Received 13 December 2014; Revised 16 February 2015; Accepted 5 March 2015

Academic Editor: Ron Ram

Copyright © 2015 Huaquan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Scheinberg and N. S. Young, “How I treat acquired aplastic anemia,” Blood, vol. 120, no. 6, pp. 1185–1196, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Vadhan-Raj, C. F. Verschraegen, C. Bueso-Ramos et al., “Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer,” Annals of Internal Medicine, vol. 132, no. 5, pp. 364–368, 2000. View at Google Scholar · View at Scopus
  3. M. Peck-Radosavljevic, M. Wichlas, J. Zacherl et al., “Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production,” Blood, vol. 95, no. 3, pp. 795–801, 2000. View at Google Scholar · View at Scopus
  4. S. Nomura, K. Dan, T. Hotta, K. Fujimura, and Y. Ikeda, “Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura,” Blood, vol. 100, no. 2, pp. 728–730, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. X.-Y. Lin, S. Hanada, K. Uozumi et al., “Serum levels of endogenous thrombopoietin and granulocyte-colony stimulating factor in patients with acute or lymphoma type adult T-cell leukemia during multicycle chemotherapy,” Leukemia and Lymphoma, vol. 43, no. 2, pp. 343–349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Townsley, R. Desmond, C. E. Dunbar, and N. S. Young, “Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes,” International Journal of Hematology, vol. 98, no. 1, pp. 48–55, 2013. View at Publisher · View at Google Scholar
  7. M. J. Olnes, P. Scheinberg, K. R. Calvo et al., “Eltrombopag and improved hematopoiesis in refractory aplastic anemia,” The New England Journal of Medicine, vol. 367, no. 1, pp. 11–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. C. W. Marsh, S. E. Ball, J. Cavenagh et al., “Guidelines for the diagnosis and management of aplastic anaemia,” British Journal of Haematology, vol. 147, no. 1, pp. 43–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. N. S. Young, R. T. Calado, and P. Scheinberg, “Current concepts in the pathophysiology and treatment of aplastic anemia,” Blood, vol. 108, no. 8, pp. 2509–2519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Kaushansky, S. Lok, R. D. Holly et al., “Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin,” Nature, vol. 369, no. 6481, pp. 568–571, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Kaushansky, “The molecular mechanisms that control thrombopoiesis,” The Journal of Clinical Investigation, vol. 115, no. 12, pp. 3339–3347, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. D. J. Kuter, “New thrombopoietic growth factors,” Clinical Lymphoma & Myeloma, vol. 9, supplement 3, pp. S347–S356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Wendling and W. Vainchenker, “Thrombopoietin and its receptor,” European Cytokine Network, vol. 9, no. 3, pp. 221–231, 1998. View at Google Scholar · View at Scopus
  14. M. Ballmaier, M. Germeshausen, H. Schulze et al., “C-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia,” Blood, vol. 97, no. 1, pp. 139–146, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. F. V. Corazza, “Physiopathologic aspects of anemia and thrombocytopenia in children with cancers: the roles of erythropoietin and thrombopoietin,” Bulletin et Mémoires de l'Académie Royale de Médecine de Belgique, vol. 163, no. 1-2, pp. 152–157, 2008. View at Google Scholar · View at Scopus
  16. R. V. B. Emmons, D. M. Reid, R. L. Cohen et al., “Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction,” Blood, vol. 87, no. 10, pp. 4068–4071, 1996. View at Google Scholar · View at Scopus
  17. R. Desmond, D. M. Townsley, B. Dumitriu et al., “Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug,” Blood, vol. 123, no. 12, pp. 1818–1825, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Qian, N. Buza-Vidas, C. D. Hyland et al., “Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells,” Cell Stem Cell, vol. 1, no. 6, pp. 671–684, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Edvardsson, J. Dykes, and T. Olofsson, “Isolation and characterization of human myeloid progenitor populations—TpoR as discriminator between common myeloid and megakaryocyte/erythroid progenitors,” Experimental Hematology, vol. 34, no. 5, pp. 599–609, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. D. C. Liang, L. Y. Shih, I. J. Chai et al., “The synergistic effect of thrombopoietin in erythropoiesis with erythropoietin and/or IL-3 and myelopoiesis with G-CSF or IL-3 from umbilical cord blood cells of premature neonates,” Pediatric Hematology and Oncology, vol. 19, no. 6, pp. 399–405, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Komatsu, T. Okamoto, T. Yoshida et al., “Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS),” Blood, vol. 96, article 296a, 2000. View at Google Scholar